E3 PreliminaryPreliminaryPEM ?Peer-reviewedMachine draft
Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.
Inui, Toshio, Kubo, Kentaro, Kuchiike, Daisuke et al. · Anticancer research · 2015
Quick Summary
This study looked at whether a substance called macrophage-activating factor (MAF), derived from cow colostrum (first milk after birth), could help three patients with chronic fatigue syndrome and serious infections. The researchers found that patients who took oral MAF experienced improvements in fatigue and infection symptoms without serious side effects. While these are promising early observations, the study is very small and would need much larger testing to know if this treatment truly works.
Why It Matters
This study is relevant because it explores a potential immune-modulating therapy targeting macrophage function, which has been implicated in ME/CFS pathophysiology. For ME/CFS patients seeking treatment options, case reports of novel therapies can generate hypotheses for future clinical trials. Understanding whether immune-based interventions like MAF warrant rigorous investigation is important for expanding the therapeutic pipeline.
Observed Findings
- Three patients with CFS and/or serious infections reported subjective improvement in fatigue symptoms after oral colostrum MAF treatment
- No serious adverse effects were reported in any of the three cases
- Authors noted improvements in infection-related symptoms in patients with concurrent infections
- Oral colostrum MAF demonstrated detectable macrophage phagocytic activity in laboratory assays
Inferred Conclusions
- Oral colostrum MAF may be a potentially safe intervention for CFS and serious infections
- Macrophage-activating factor warrants further investigation as a possible supportive or adjunctive therapy
- Oral colostrum MAF could be explored for immune-related symptoms across multiple chronic conditions
Remaining Questions
- What is the optimal dose and duration of oral colostrum MAF treatment?
- How does oral colostrum MAF compare to placebo or standard care in randomized controlled trials?
- Which specific ME/CFS patient subgroups, if any, might benefit from MAF-based immunotherapy?
- What are the mechanisms by which colostrum-derived MAF affects macrophage function and symptom improvement in ME/CFS?
What This Study Does Not Prove
This study does not prove that oral MAF is effective for ME/CFS or infections. As case reports without controls, comparisons, or blinded assessment, the improvements described could result from natural recovery, placebo effect, or coincidental resolution. The small sample size and lack of objective biomarkers mean causality cannot be established, and findings cannot be generalized.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only
Metadata
- PMID
- 26168499
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026